

Bilag

**Bilag 1 – svar på SUU alm. del spørgsmål 1143**

**Table 1: Opgørelse over internationale forskningsprojekter**

	Forskningsinstitution	Navn på forskningsprojekt	Samarbejdsparts institution/ organisation	Hjemsted (land)	Dato for projektaftale
1	Københavns Universitet Amager og Hvidovre Hospital	CelCradle™ System Trial Agreement, Terms, and Conditions - HCV Vaccine Development (inactivated virus vaccine)	Esco Aster	Singapore	12-06-2018
2	Københavns Universitet Amager og Hvidovre Hospital	Mutual Non Disclosure Agreement – SARS-CoV-2 and HCV Vaccine Development (inactivated virus vaccines)	Esco Aster	Singapore	01-05-2020
3	Københavns Universitet Amager og Hvidovre Hospital	Research Cooperation Contract: Chromatographic Purification of Inactivated Cell Culture Derived HCV	University of Applied Sciences (Giessen)	Tyskland	09-04-2018
4	Københavns Universitet Amager og Hvidovre Hospital	Animal cell culture based viral vaccine production. HCV and SARS-CoV-2	Max Planck Institute for Dynamics of Complex Technical Systems	Tyskland	01-05-2020*
5	Københavns Universitet Amager og Hvidovre Hospital	NDA and MTA relating to cell line used for SARS-CoV-2 vaccine development (inactivated virus vaccine)	Nuvonis	Østrig	01-04-2020
6	Københavns Universitet Herlev og Gentofte Hospital	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity Prevent-nCoV (H2020 Research & Innovation Action)	AdaptVac ApS (DK) Eberhard Karls Universität (DE) Universitätsklinikum Tübingen (DE) ExpreS2ion Biotechnologies ApS (DK)	Tyskland Nederlandene	01-04-2020

23. juni 2021

**Uddannelses- og  
 Forskningsministeriet**  
 Forsknings- og Innovationspolitik

Børsgade 4  
 Postboks 2135  
 1015 København K  
 Tel. 3392 9700

[www.ufm.dk](http://www.ufm.dk)

CVR-nr. 1680 5408

			Wageningen University (NL) Academisch Ziekenhuis Leiden (NL) Stichting Katholieke Universiteit - Radboud University Medical Center (NL)		
7	Nordsjællands hospital	A phase 3, randomized, double- or observer-blinded, placebo-controlled trial to evaluate the efficacy and safety of a respiratory syncytial virus (RSV) prefusion fsubunit vaccine in infants born to women vaccinated during pregnancy	Pfizer	USA	29-06-2020
8	Rigshospitalet	SARS-CoV-2 vaccination strategies in previously hospitalised and recovered COVID-19 patients (VATICO),	INSIGHT network (funded by NIAID and NIH)	USA	2021**
9	Syddansk Universitet	Samarbejde vedr. E. coli strains	GSK Vaccines Srl	Italien	03-06-2020
10	Syddansk Universitet	Bandim Health Projekt	Guinea Bissau (stat)	Guinea Bissau	N/A
11	Syddansk Universitet	Samarbejdsaftale vedr. projektet "Mulige bivirkninger ved HPV vaccine blandt nordiske piger og drenge: Påvirker det uddannelsesforløbet?"	Tampere University Foundation sr Norwegian Institute of Public Health	Finland Norge	15-06-2020
12	Aalborg Universitet	Development of AAVLP vaccine platform. Development of Vitiligo vaccine, Head and Neck cancer vaccine, HIV vaccine, HPV vaccine, Pan-Corona virus vaccine and Pan Ebola virus vaccine	For Pan-Coronavirus vaccine and Pan-Ebolavirus vaccine collaboration with Stony Brook university USA and John Jay CUNY college of Criminal Justice New York, USA.	USA	01-01-2017

13	Statens Serum Institut	Developing a Chlamydia Trachomatis vaccine — TracVac'	Imperial college of science technology and medicine (Imperial); London school of hygiene and tropical medicine (LSHTM); Commissariat a l energie atomique et aux energies alternatives (CEA)	UK Frankrig	01-03-2017
14	Statens Serum Institut	European Vaccine Research and Development Infrastructure — TRANSVAC2	European vaccine initiative EWIV (EVI) + 25 andre partnere	Tyskland	01-05-2017
15	Statens Serum Institut	POR TB consortium; Phase 2 trial to determine efficacy of the multistage vaccine H56:IC31 for Prevention Of Recurrent TB disease	International AIDS Vaccine Initiative, South Africa + 6 andre partnere	Sydafrika Tanzania	01-11-2017
16	Statens Serum Institut	A dual function TB subunit vaccine designed for non-interference with BCG and post-exposure activity	Seattle Children's Research Institute (NIH midler)	USA	01-12-2017
17	Statens Serum Institut	Eliciting lung-localized CD4 T cell responses against Mycobacterium tuberculosis in preventive and post-exposure settings	Seattle Children's Research Institute (NIH midler)	USA	22-08-2017
18	Statens Serum Institut	Novel vaccine vectors to resist pathogen challenge' — 'VacPath'	Coordinator: Universiteit Utrecht + 7 andre partnere	Holland	01-01-2019
19	Statens Serum Institut	Rapid evaluation of Plasmodium falciparum transmission Blocking Vaccine	Coordinator: Université des Sciences, des Techniques et des	Mali	01-01-2019

		(PFTBV) candidates through enhanced African Resource Centers (ARC) for integration into malaria control and elimination — PFTBV	Technologies de Bamako (USTTB) + 7 andre partnere		
20	Statens Serum Institut	A nanovaccine Approach for the treatment of Pancreatic Cancer' — 'PAVE'	Coordinator: Percuros BV + 13 andre partnere	Holland	01-10-2019
21	Statens Serum Institut	Nanobodies and antibodies against 2019-nCoV' — 'CoroNAb'	Koordinator: Karolinska Institutet + 3 andre partnere	Sverige	01-04-2020
22	Statens Serum Institut	Recombinant CSP Bill & Melinda Gates Foundation funding (contract no.: INV-003390)	Coordinator: SSI	N/A	01-11-2019
23	Statens Serum Institut	Optimizing a deployable high efficacy malaria vaccine (H2020 contract no.: 733273)	Coordinator: Oxford	UK	01-01-2017
24	Statens Serum Institut	Functional immune-genetic correlates of malaria immunity. Danish Ministry of Foreign Affairs (DFC file no.14-P01-GHA)	Coordinator: The Noguchi Memorial Institute for Medical Research	Ghana	01-01-2016
25	Statens Serum Institut	Development of "27-383H-CSP" P. falciparum circumsporozoite protein (rPfCSP) for non-clinical use L. lactis. PATH	Coordinator: SSI	Ikke oplyst	01-02-2018
26	Statens Serum Institut	Process development and formulation studies of R0.6C. PATH	Coordinator: SSI	N/A	01-12-2018
27	Statens Serum Institut	Development of P. falciparum UIS 3 constructs in L. lactis. PATH	Coordinator: SSI	N/A	11-04-2018

28	Statens Serum Institut	Construct development and pilot production of a Glideosome-associated protein 40 (GAP40) in grampositive bacteria and yeast. PATH	Coordinator: SSI	Ikke oplyst	17-01-2018
29	Statens Serum Institut	Broad Influenza Virus Vaccine (BROADWA-II) /TRANSVAC2 transnational access	Commissariat a l'energie atomique et aux energies alternatives (CEA)	Frankrig	01-06-2018
30	Statens Serum Institut	Broad Influenza Virus Vaccine (BROADWA-IIa) /TRANSVAC2 transnational access	Commissariat a l'energie atomique et aux energies alternatives (CEA)	Frankrig	02-11-2019
31	OUH / Region Syddanmark	Sugar-modified Vaccine Epitopes; exploration and Trans	GlyProVac, epitopic GmbH, Fraunhofer Gesellschaft	Tyskland	03-11-2020
32	OUH / Region Syddanmark	Study MEQ00065 – MenACYW conjugate vaccine: Meningococcal Polysaccharide (Serogroups A, C, W and Y) Tetanus Toxoid Conjugate Vaccine	Sanofi Pasteur	Frankrig	06-06-2019
33	OUH / Region Syddanmark	Influenza vaccination After Myocardial Infarction (IAMI) trial	School of Medical Sciences, Örebro University	Sverige	01-07-2017

\* Kontrakten er ved at blive afsluttet. Vil blive dateret tilbage til maj 2020

\*\* Forventet opstart i 2021